益盛药业(002566) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥217,121,787.36, a decrease of 9.74% year-on-year, while year-to-date revenue was ¥614,016,426.03, down 17.68% compared to the same period last year[9] - Net profit attributable to shareholders for the reporting period was ¥21,344,867.38, an increase of 39.86% year-on-year, with year-to-date net profit at ¥54,188,768.07, a slight decrease of 2.03%[9] - Basic earnings per share for the reporting period were ¥0.0645, up 39.91% year-on-year, with diluted earnings per share also at ¥0.0645[9] - Total operating revenue for the third quarter was CNY 217,121,787.36, a decrease from CNY 240,548,305.91 in the previous period[40] - The total profit for the third quarter was CNY 29,036,243.91, an increase of 55.4% from CNY 18,694,158.23 in the same period last year[42] - The net profit for the third quarter reached CNY 24,811,661.81, representing a 64.4% increase from CNY 15,131,185.24 year-over-year[42] - The company's operating revenue for the third quarter of 2020 was CNY 482.75 million, a decrease of 17% compared to CNY 580.90 million in the same period last year[53] - The net profit attributable to the parent company was CNY 54.19 million, down 2% from CNY 55.31 million year-on-year[51] Assets and Liabilities - Total assets at the end of the reporting period reached ¥2,656,227,086.82, an increase of 6.40% compared to the end of the previous year[9] - Total liabilities rose to CNY 551,133,312.55, up from CNY 438,662,072.17, indicating an increase of about 25.6%[34] - Current liabilities totaled CNY 495,421,577.39, compared to CNY 396,009,424.20, marking an increase of approximately 25.1%[34] - Non-current liabilities increased to CNY 55,711,735.16 from CNY 42,652,647.97, representing a growth of about 30.6%[34] - Owner's equity totaled CNY 2,105,093,774.27, up from CNY 2,057,851,599.06, showing an increase of approximately 2.3%[35] - Total assets increased to CNY 2,656,227,086.82 from CNY 2,496,513,671.23, reflecting a growth of approximately 6.4%[35] - Shareholders' equity totaled CNY 2,057,851,599.06, including CNY 330,951,600.00 in share capital and CNY 662,061,469.59 in undistributed profits[67] Cash Flow - The net cash flow from operating activities was ¥41,286,087.37, a significant increase of 391.10% compared to the same period last year, while year-to-date cash flow decreased by 37.04%[9] - Cash flow from operating activities decreased by 37.04% to ¥80,995,109.69 from ¥128,646,977.15, mainly due to reduced cash payments related to operating activities[19] - The net cash flow from operating activities for Q3 2020 was ¥80,995,109.69, a decrease of 37.0% compared to ¥128,646,977.15 in Q3 2019[58] - Total cash inflow from operating activities was ¥698,939,437.12, down 19.6% from ¥869,039,329.29 in the previous year[58] - Cash outflow from operating activities totaled ¥617,944,327.43, a decrease of 16.5% compared to ¥740,392,352.14 in Q3 2019[58] - The net cash flow from investing activities was -¥5,049,230.35, compared to -¥15,296,426.17 in the same period last year, indicating an improvement[59] - Cash inflow from financing activities was ¥485,000,000.00, an increase of 50.4% from ¥322,550,000.00 in Q3 2019[59] - The net cash flow from financing activities was ¥99,539,423.01, compared to -¥90,838,686.33 in the previous year, showing a significant turnaround[59] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,486[13] - The largest shareholder, Zhang Yisheng, holds 39.08% of the shares, totaling 129,348,530 shares[13] - The company has not conducted any repurchase transactions among the top 10 shareholders during the reporting period[14] Government Subsidies and Investments - Other income surged by 140.17% to ¥17,864,094.02 from ¥7,438,032.81, primarily due to increased government subsidies received[19] - The company received a total of ¥7,196,800 in government subsidies from January 1 to April 13, 2020, and ¥15,680,700 from April 13 to August 18, 2020[21] - The company plans to invest ¥344,790,000 in the construction of a ginseng deep processing industry project, requiring 223.5 acres of land[21] Expenses - The company reported a significant increase in financial expenses, which decreased by 41.28% to ¥7,715,363.07 from ¥13,139,246.29, due to a reduction in the average balance of short-term borrowings[19] - Research and development expenses decreased to CNY 5,413,750.43, a reduction of 24.6% compared to CNY 7,187,456.00 in the previous year[41] - Sales expenses for the third quarter were CNY 108,494,192.12, down 15.9% from CNY 128,943,551.63 year-over-year[41] - The income tax expense for the quarter was CNY 10.48 million, compared to CNY 12.33 million in the same period last year, reflecting a decrease of about 15%[50] Other Financial Metrics - The weighted average return on net assets was 1.09%, an increase from 0.29% in the previous year[9] - The company reported a credit impairment loss of CNY -496,729.74, significantly improved from CNY -6,292,297.70 in the previous year[41] - The company reported a credit impairment loss of CNY -4.43 million, an improvement from CNY -7.39 million in the previous year[50] - The total comprehensive income for the third quarter was CNY 24,811,661.81, compared to CNY 15,131,185.24 in the same period last year, reflecting a growth of 64.4%[43] - The total comprehensive income for the third quarter was CNY 63.79 million, down from CNY 68.31 million year-on-year[51]